Video yükleniyor...

Video Yüklenemedi

Ana Sayfaya Dön

Real talk — I’ve been thinking about the Wolverine stack and it makes zero sense to me to put BPC-157 and TB-500 in the same vial. These two have totally different half-lives and ideal dosing schedules. BPC wants to be in there daily, TB-500 shines with bigger doses a...

18,258 görüntüleme • 11 gün önce •via X (Twitter)

0 Yorum

Yorum bulunmuyor

Orijinal gönderinin yorumları burada görünecek

Benzer Videolar

BPC-157 and TB-500 are two of the most talked-about peptides in fitness, bodybuilding, and biohacking. Together they’re often called the “Wolverine Stack” — a peptide combination rumored to dramatically accelerate healing of tendons, ligaments, muscles, and injuries. But do BPC-157 and TB-500 actually work in humans, or is the Wolverine Stack just another example of internet bro-science? In this evidence-based deep dive, Dr. Alex Tatem (board-certified urologist and men’s health specialist) breaks down the real science behind BPC-157 and TB-500 — including their biochemical mechanisms, animal research, potential healing effects, safety concerns, and why pharmaceutical companies have never brought these peptides through full FDA clinical trials. We explore the nitric oxide signaling, angiogenesis, VEGF pathways, actin regulation, and tissue repair biology behind these compounds and explain why rodent studies look promising — but why human clinical evidence is still extremely limited. You’ll also learn about: • What BPC-157 (Body Protection Compound-157) actually is • TB-500 vs Thymosin Beta-4 explained • The origin of the Wolverine Stack peptide protocol • Peptides for tendon healing and ligament injuries • BPC-157 for gut healing and musculoskeletal repair • TB-500 and actin-mediated tissue regeneration • Why most peptide research comes from one Croatian research group • The patent law problem preventing pharmaceutical development • Real risks of grey-market peptide contamination • Why WADA bans BPC-157 and TB-500 in competitive athletes • Theoretical cancer risks related to angiogenesis • What the current scientific literature actually shows If you've ever searched: “Does BPC-157 work?” “What is TB-500?” “Peptides for healing injuries” “BPC-157 tendon repair” “Wolverine Stack peptides explained” — this video breaks down the science. The peptides may be promising. But promise and proof are not the same thing. Drop a comment below: Have you ever used BPC-157, TB-500, or other peptides? What was your experience? 👍 Like the video if you want more evidence-based breakdowns of supplements, PEDs, and peptides. Subscribe for deep dives on testosterone, steroids, peptides, supplements, and men’s health science.

Dr. Alex Tatem

21,218 görüntüleme • 4 ay önce

Frank Slootman: “Being a CEO is a highly confrontational role” “I’ve gone one record a few times and people have taken me to task on it, when I’ve said that being a CEO is a highly confrontational role. But they think that ‘confrontational’ means I’m grabbing people by the lapels and slamming them against the wall and yelling. That’s not what I mean by confrontation.” The former CEO of Snowflake and ServiceNow continues: “Confrontation is about confronting issues and situations. When you see something that is either not good, not good enough, or can be better, you need to talk to the team and people responsible to bring them along in your thinking.” In Frank’s view, the framing should be: “this is why I am saying this, what do you think?” The goal of the conversation is to help them see the problems you’re seeing. You should be driving them to a “higher level of aspiration,” he explains. “I often start the conversation with, ‘How do you think things are going?’ I’m not telling them ‘you suck,’ or ‘things are terrible.’ Let them talk. And then you can say, ‘Well what about this?’ And all of a sudden, the perspective has opened up and changed. So the challenge is bringing them along in your thinking — then it’s not confrontational… Obviously there’s finesse and subtlety. You’re dealing with people. You don’t want to destroy them. You want to build them, not bring them down.” You need to help them grow: “People have a tendency to go sideways. They rinse and repeat and keep doing the same things. You can’t in a high-growth company. You need to become a different version of yourself. I’m trying to help them think through that. What does that look like? What does your organization look like a year from now versus what it looks like today?… In other words, stimulate their thinking. Challenge them to think about what they should do differently next week. Is that confrontation? Yes it is, but it’s dressed up in a way that it engages people.” Frank believes founders should be doing this every single week. Video source: Foundation Capital (2024)

Startup Archive

100,750 görüntüleme • 9 ay önce

Frank Slootman: “Being a CEO is a highly confrontational role” “I’ve gone one record a few times and people have taken me to task on it, when I’ve said that being a CEO is a highly confrontational role. But they think that ‘confrontational’ means I’m grabbing people by the lapels and slamming them against the wall and yelling. That’s not what I mean by confrontation.” The former CEO of Snowflake and ServiceNow continues: “Confrontation is about confronting issues and situations. When you see something that is either not good, not good enough, or can be better, you need to talk to the team and people responsible to bring them along in your thinking.” In Frank’s view, the framing should be: “this is why I am saying this, what do you think?” The goal of the conversation is to help them see the problems you’re seeing. You should be driving them to a “higher level of aspiration,” he explains. “I often start the conversation with, ‘How do you think things are going?’ I’m not telling them ‘you suck,’ or ‘things are terrible.’ Let them talk. And then you can say, ‘Well what about this?’ And all of a sudden, the perspective has opened up and changed. So the challenge is bringing them along in your thinking — then it’s not confrontational… Obviously there’s finesse and subtlety. You’re dealing with people. You don’t want to destroy them. You want to build them, not bring them down.” You need to help them grow: “People have a tendency to go sideways. They rinse and repeat and keep doing the same things. You can’t in a high-growth company. You need to become a different version of yourself. I’m trying to help them think through that. What does that look like? What does your organization look like a year from now versus what it looks like today?… In other words, stimulate their thinking. Challenge them to think about what they should do differently next week. Is that confrontation? Yes it is, but it’s dressed up in a way that it engages people.” Frank believes founders should be doing this every single week. Video source: Foundation Capital (2024)

Startup Archive

136,616 görüntüleme • 1 yıl önce

BPC-157 causing cancer? FDA shutting down peptide trials? “No human RCTs have ever been done on peptides?” In this video, Dr. Alex Tatem — board-certified urologist and fellowship-trained men’s health specialist — reacts to viral claims made on Shawn Ryan Show about BPC-157, TB-500, peptides, angiogenesis, cancer risk, and peptide safety. We break down: • Whether BPC-157 actually causes cancer • The truth about angiogenesis and tumor growth • FDA regulation of peptides and compounding • Why the “no randomized controlled trials” claim is completely false • Human clinical trial data on peptides • The real history of BPC-157 clinical studies • Huberman’s correction of viral peptide misinformation • Why peptide fearmongering could push patients toward unsafe gray-market sourcing This is not bro-science or influencer hype. This is a deep dive into the actual published literature, peptide pharmacology, FDA policy, and performance medicine. Topics covered include: BPC-157, TB-500, peptides, angiogenesis, cancer biology, GLP-1 drugs, Ozempic, tirzepatide, semaglutide, TRT, peptide therapy, biohacking, longevity, anti-aging medicine, compounding pharmacies, peptide legality, Andrew D. Huberman, Ph.D. , Shawn Ryan Show, FDA peptide regulation, growth hormone history, and performance medicine. If you’ve ever wondered whether BPC-157 is dangerous, whether peptides are legal, or whether the internet is fearmongering about peptide therapy — this video is for you.

Dr. Alex Tatem

75,971 görüntüleme • 2 ay önce

Joe Rogan takes BPC-157. Huberman takes BPC-157. The US Health Secretary called himself a “big fan” of peptides. Your doctor has never heard of it. BPC-157. 15 amino acids. Found in your own stomach juice. Rogan had elbow tendonitis nothing could fix. BPC-157 — gone in two weeks. Called it “Wolverine shit.” Huberman had chronic back pain from a herniated disc. Two injections. Years of pain — gone. He’s a Stanford neuroscientist. He doesn’t exaggerate. RFK Jr. uses peptides for his own injuries. The FDA is now reclassifying BPC-157 toward legal access. in studies: → REGREW severed nerves → REBUILT torn ligaments — oral worked → REATTACHED tendon to bone → 90% relief in 16 knee patients → REVERSED alcohol damage across 7 organs → HEALED bone defects comparable to grafts “doesn’t it cause cancer?” let me be clear: → in 30+ years of research — NOT ONE documented case of BPC-157 causing or promoting cancer. not one. → a 2018 study actually REDUCED tumor formation → the angiogenesis BPC triggers is REGULATED — it heals damaged tissue and stops. tumor growth uses different pathways entirely. but — if you have an active cancer diagnosis, don’t take it. not because the data shows harm. because it hasn’t been tested in cancer patients specifically. that decision belongs to your oncologist. not me. not a podcast. your oncologist. 30 years. zero lethal dose. zero cancer. used by the biggest names in health. your doctor won’t mention it. your stomach already makes it. I take it daily. source in the comments ↓

Healthy Alfred 🌴🥥

323,157 görüntüleme • 1 ay önce